Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BI-1808 |
Trade Name | |
Synonyms | BI 1808|BI1808 |
Drug Descriptions |
BI-1808 is an antibody that targets TNFR2, potentially leading to modulation of the antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 4156). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C179618 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BI-1808 | BI-1808 | 0 | 1 |
BI-1808 + Pembrolizumab | BI-1808 Pembrolizumab | 0 | 1 |